LIVE MARKET TRACKER :   BSE SENSEX   32584.35      |    NSE NIFTY 10210.85    
GLOBAL MARKETS :  NASDAQ 6624.22   +0.01%    |    FSI London 7542.87   +0.36%    |    NIKKEI Japan 21425.55   +0.29%
  USD GBP EUR CAD AUD INR
USD - 0.7566 0.8476 1.2469 1.2730 65.0890
GBP 1.3218 - 1.1202 1.6481 1.6823 86.0490
EUR 1.1801 0.8928 - 1.4714 1.5020 76.7966
CAD 0.8025 0.6074 0.6799 - 1.0216 52.2120
AUD 0.7857 0.5946 0.6660 0.9797 - 51.0900
INR 0.0154 0.0116 0.0130 0.0192 0.0196 -
Indian-Commodity  :  Equity & Shares  :  Lupin gains on receiving FDA approval for Potassium Chloride Extended Release Capsules

Lupin gains on receiving FDA approval for Potassium Chloride Extended Release Capsules (18-Aug-2016)

Lupin is currently trading at Rs. 1597.20, up by 1.90 points or 0.12% from its previous closing of Rs. 1595.30 on the BSE.

The scrip opened at Rs. 1598.00 and has touched a high and low of Rs. 1607.65 and Rs. 1591.50 respectively. So far 34,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1607.65 and Rs. 1568.50 respectively. The current market cap of the company is Rs. 72,030.00 crore.

The promoters holding in the company stood at 46.76%, while Institutions and Non-Institutions held 42.40% and 10.83% respectively.

Lupin's US subsidiary, Gavis Pharmaceuticals LLC., USA (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million as per IMS MAT March 2016 data.

Lupin's Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.





Top News Today
Suven Life Sciences secures product patent in Singapore
(18-Oct-2017)

Suven Life Sciences secures product patent in SingaporeSuven Life Sciences has secured one product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents......click on news to read complete article.

Jubilant Life Sciences issues commercial papers worth Rs 50 crore
(18-Oct-2017)

Jubilant Life Sciences issues commercial papers worth Rs 50 croreJubilant Life Sciences has issued Commercial Papers (CPs) aggregating to Rs 50 crore on October 17, 2017. The company has issued two commercial papers of Rs 25 crore each providing an interest rate of......click on news to read complete article.

Peninsula Land receives Rs 200 crore from Godrej Skyline for Pune land
(18-Oct-2017)

Peninsula Land receives Rs 200 crore from Godrej Skyline for Pune landPeninsula Land has received Rs 200 crore out of the total consideration of Rs 226 crore from Godrej Skyline Developers for sale of property situated at Village Mamurdi, Taluka Haveli, District - Pune,......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Wednesday
(18-Oct-2017)

Asian markets trade mostly lower in early deals on WednesdayMost of the Asian equity benchmarks are trading lower in the early deals on Wednesday with investors trading cautiously as China's President Xi Jinping spoke at the beginning of the Communist Party's 19th......click on news to read complete article.

US markets closed mostly higher on round of positive earnings report
(18-Oct-2017)

US markets closed mostly higher on round of positive earnings reportThe US markets closed mostly higher on Tuesday, with both the Dow and the S&P 500 finishing at records as a round of positive earnings report from major companies boosted positive sentiment and......click on news to read complete article.

Asian markets trade mostly higher in early deals on Tuesday
(17-Oct-2017)

Asian markets trade mostly higher in early deals on TuesdayMost of the Asian equity benchmarks are trading in green in the early deals on Tuesday, with the fresh record highs on Wall Street and firm commodity prices boosting investors' sentiments. Comments by......click on news to read complete article.

 

     
  
Recent Equity & Shares News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.